BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

871 related articles for article (PubMed ID: 18171295)

  • 1. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.
    Hunt PW; Brenchley J; Sinclair E; McCune JM; Roland M; Page-Shafer K; Hsue P; Emu B; Krone M; Lampiris H; Douek D; Martin JN; Deeks SG
    J Infect Dis; 2008 Jan; 197(1):126-33. PubMed ID: 18171295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy.
    Hatano H; Delwart EL; Norris PJ; Lee TH; Dunn-Williams J; Hunt PW; Hoh R; Stramer SL; Linnen JM; McCune JM; Martin JN; Busch MP; Deeks SG
    J Virol; 2009 Jan; 83(1):329-35. PubMed ID: 18945778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The independent effect of drug resistance on T cell activation in HIV infection.
    Hunt PW; Deeks SG; Bangsberg DR; Moss A; Sinclair E; Liegler T; Bates M; Tsao G; Lampiris H; Hoh R; Martin JN
    AIDS; 2006 Mar; 20(5):691-9. PubMed ID: 16514299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment.
    Emu B; Sinclair E; Favre D; Moretto WJ; Hsue P; Hoh R; Martin JN; Nixon DF; McCune JM; Deeks SG
    J Virol; 2005 Nov; 79(22):14169-78. PubMed ID: 16254352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of CD8 lymphocyte activation with cellular viremia and plasma HIV RNA levels in asymptomatic patients infected by human immunodeficiency virus type 1.
    Bouscarat F; Levacher-Clergeot M; Dazza MC; Strauss KW; Girard PM; Ruggeri C; Sinet M
    AIDS Res Hum Retroviruses; 1996 Jan; 12(1):17-24. PubMed ID: 8825614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1.
    Bello G; Velasco-de-Castro CA; Bongertz V; Rodrigues CA; Giacoia-Gripp CB; Pilotto JH; Grinsztejn B; Veloso VG; Morgado MG
    J Med Virol; 2009 Oct; 81(10):1681-90. PubMed ID: 19697415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
    Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
    Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of NK cells is associated with HIV-1 disease progression.
    Kuri-Cervantes L; de Oca GS; Avila-Ríos S; Hernández-Juan R; Reyes-Terán G
    J Leukoc Biol; 2014 Jul; 96(1):7-16. PubMed ID: 24399837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers.
    Ganesh A; Lemongello D; Lee E; Peterson J; McLaughlin BE; Ferre AL; Gillespie GM; Fuchs D; Deeks SG; Hunt PW; Price RW; Spudich SS; Shacklett BL
    AIDS Res Hum Retroviruses; 2016 Aug; 32(8):791-800. PubMed ID: 27019338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters.
    Pereyra F; Palmer S; Miura T; Block BL; Wiegand A; Rothchild AC; Baker B; Rosenberg R; Cutrell E; Seaman MS; Coffin JM; Walker BD
    J Infect Dis; 2009 Sep; 200(6):984-90. PubMed ID: 19656066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy.
    Benito JM; López M; Lozano S; Martinez P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2004 Feb; 20(2):227-33. PubMed ID: 15018711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers.
    Hunt PW; Landay AL; Sinclair E; Martinson JA; Hatano H; Emu B; Norris PJ; Busch MP; Martin JN; Brooks C; McCune JM; Deeks SG
    PLoS One; 2011 Jan; 6(1):e15924. PubMed ID: 21305005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy.
    Ostrowski SR; Katzenstein TL; Thim PT; Pedersen BK; Gerstoft J; Ullum H
    J Infect Dis; 2005 Feb; 191(3):348-57. PubMed ID: 15633093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for innate immune system activation in HIV type 1-infected elite controllers.
    Krishnan S; Wilson EM; Sheikh V; Rupert A; Mendoza D; Yang J; Lempicki R; Migueles SA; Sereti I
    J Infect Dis; 2014 Mar; 209(6):931-9. PubMed ID: 24185941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA.
    Kaufmann GR; Zaunders JJ; Cunningham P; Cooper DA
    AIDS Res Hum Retroviruses; 1999 Jul; 15(11):963-72. PubMed ID: 10445808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers.
    Rosás-Umbert M; Llano A; Bellido R; Olvera A; Ruiz-Riol M; Rocafort M; Fernández MA; Cobarsi P; Crespo M; Dorrell L; Del Romero J; Alcami J; Paredes R; Brander C; Mothe B
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmatic Levels of IL-18, IP-10, and Activated CD8
    Côrtes FH; de Paula HHS; Bello G; Ribeiro-Alves M; de Azevedo SSD; Caetano DG; Teixeira SLM; Hoagland B; Grinsztejn B; Veloso VG; Guimarães ML; Morgado MG
    Front Immunol; 2018; 9():1576. PubMed ID: 30050532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses.
    Owen RE; Heitman JW; Hirschkorn DF; Lanteri MC; Biswas HH; Martin JN; Krone MR; Deeks SG; Norris PJ;
    AIDS; 2010 May; 24(8):1095-105. PubMed ID: 20400885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe immune dysregulation affects CD4⁺CD25(hi)FoxP3⁺ regulatory T cells in HIV-infected patients with low-level CD4 T-cell repopulation despite suppressive highly active antiretroviral therapy.
    Méndez-Lagares G; Pozo-Balado MM; Genebat M; García Pergañeda A; Leal M; Pacheco YM
    J Infect Dis; 2012 May; 205(10):1501-9. PubMed ID: 22457273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.